Chinese Biotech Shares Surge on Optimism for Cutting-Edge Cancer Treatments and Licensing Deals

Strategic Insights -

A surge in biotech shares in China has left investors optimistic about the future of the sector, driven by a wave of exciting cancer treatments and strategic licensing deals with global pharmaceutical giants. The Hang Seng Biotech Index has seen a remarkable 61.8% increase in value year-to-date, making biotech one of the standout performers in China's capital markets in 2024. After a years-long downturn, the sector is experiencing a revival, thanks to robust innovation, favorable clinical results, and cost-effective research and development capabilities.

Key Takeaways:

  • The Hang Seng Biotech Index has soared 61.8% year-to-date, making biotech one of the standout performers in China's capital markets in 2024.
  • The resurgence is driven by a class of immunotherapy drugs known as PD-1 inhibitors, which are increasingly showing promise in treating a wide range of cancers.
  • Chinese companies are developing next-generation variants, including PD-1 VEGF combinations, that are producing strong clinical outcomes and attracting attention from major Western pharmaceutical firms.
  • 3SBio, a Shenyang-based company, inked a licensing deal with Pfizer in May for its PD-1 therapy, netting an upfront payment of $1.25 billion, with its stock skyrocketing 318% this year.
  • Akeso, a biotech headquartered in Guangdong, has demonstrated that its PD-1 drugs can go toe-to-toe with Merck's blockbuster immunotherapy, Keytruda, with its shares jumping 92% year-to-date.
  • Chinese firms are developing new therapies at a fraction of the cost of their Western peers, thanks to lower labor, manufacturing, and trial costs.
  • Several top-tier Chinese biotechs have already reached profitability in 2024, an uncommon milestone in a sector often characterized by extended pre-revenue development phases.
  • Regulatory focus remains on preserving the economic strength of domestic pharma giants, despite US-China tensions and threats of tariffs on Chinese pharma products.

Statistics:

  • 61.8%: year-to-date increase in the Hang Seng Biotech Index.
  • 3SBio: $1.25 billion upfront payment from Pfizer for its PD-1 therapy licensing deal.
  • 318%: increase in 3SBio's stock price this year.
  • Akeso: 92% year-to-date increase in its stock price.
  • 86%: increase in Hansoh Pharma's stock price this year, driven by its $1.9 billion exclusive licensing agreement with Merck for its GLP-1 weight-loss drug.

Sources:

  • Financial Times
  • Shannon Cheung, co-founder of Likang Life Sciences
  • Jialin Zhang, head of China healthcare research at Nomura
  • Cui Cui, head of Asia healthcare research at Jefferies
  • Emily Dong, head of equity at Conning Asia Pacific